Vesicular stomatitis virus–based vaccines against lassa and ebola viruses

Emerging Infectious Diseases

Volumn 21, Issue 2, 2015, Pages 305-307

  Marzi, Andrea ^a   Feldmann, Friederike ^a   Geisbert, Thomas W ^b   Feldmann, Heinz ^a   Safronetz, David ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EBOLA VACCINE; GLYCOPROTEIN; NUCLEOCAPSID PROTEIN; VIRUS VACCINE; RECOMBINANT VACCINE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; AMYLASE BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD SAMPLING; EBOLA HEMORRHAGIC FEVER; EBOLA VIRUS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNE RESPONSE; LASSA FEVER; LASSA VIRUS; LYMPHOCYTOPENIA; NONHUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEROCONVERSION; THROMBOCYTOPENIA; UREA NITROGEN BLOOD LEVEL; VESICULOVIRUS; VIREMIA; VIRUS HEMORRHAGIC FEVER; VIRUS ISOLATION; ANIMAL; DISEASE MODEL; EBOLAVIRUS; GENE VECTOR; HEMORRHAGIC FEVER, EBOLA; IMMUNOLOGY; MACACA FASCICULARIS; MORTALITY; VACCINATION; VESICULAR STOMATITIS INDIANA VIRUS;

ANIMALS; DISEASE MODELS, ANIMAL; EBOLAVIRUS; GENETIC VECTORS; HEMORRHAGIC FEVER, EBOLA; HUMANS; LASSA FEVER; LASSA VIRUS; MACACA FASCICULARIS; VACCINATION; VACCINES, SYNTHETIC; VESICULAR STOMATITIS INDIANA VIRUS; VIRAL VACCINES;

EID: 84921818775     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid2102.141649     Document Type: Article

References (12)

1. Falzarano D, Feldmann H. Vaccines for viral hemorrhagic feversprogress and shortcomings. Curr Opin Virol. 2013;3:343–51. http://dx.doi.org/10.1016/j.coviro.2013.04.007
2. DeBuysscher BL, Scott D, Marzi A, Prescott J, Feldmann H. Single-dose live-attenuated Nipah virus vaccines confer complete protection by eliciting antibodies directed against surface glycoproteins. Vaccine. 2014;32:263 44. http://dx.doi.org/10.1016/j.vaccine.2014.02.0877
3. Jones SM, Feldmann H, Stroher U, Geisbert JB, Fernando L, Grolla A, et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med. 2005;11:786–90. http://dx.doi.org/10.1038/nm1258
4. Geisbert TW, Jones S, Fritz EA, Shurtleff AC, Geisbert JB, Liebscher R, et al. Development of a new vaccine for the prevention of Lassa fever. PLoS Med. 2005;2:e183. http://dx.doi.org/10.1371/journal.pmed.0020183
5. Brown KS, Safronetz D, Marzi A, Ebihara H, Feldmann H. Vesicular stomatitis virus-based vaccine protects hamsters against lethal challenge with Andes virus. J Virol. 2011;85:12781 91. http://dx.doi.org/10.1128/JVI.00794-11
6. Geisbert TW, Geisbert JB, Leung A, Daddario-DiCaprio KM, Hensley LE, Groll A, et al. Single-injection vaccine protects nonhuman primates against infection with Marburg virus and three species of Ebola virus. J Virol. 2009;83:7296–304. http://dx.doi.org/10.1128/JVI.00561-09
7. Mire CE, Geisbert JB, Marzi A, Agans KN, Feldmann H, Geisbert TW. Vesicular stomatitis virus-based vaccines protect nonhuman primates against Bundibugyo ebolavirus. PLoS Negl Trop Dis. 2013;7:e2600. http://dx.doi.org/10.1371/journal.pntd.0002600
8. WHO Ebola Response Team. Ebola virus disease in West Africa-the first 9 months of the epidemic and forward projections. N Engl J Med. 2014;371:1481–95. http://dx.doi.org/10.1056/NEJMoa1411100
9. Safronetz D, Strong JE, Feldmann F, Haddock E, Sogoba N, Brining D, et al. A recently isolated Lassa virus from Mali demonstrates atypical clinical disease manifestations and decreased virulence in cynomolgus macaques. J Infect Dis. 2013;207: 1316–27. http://dx.doi.org/10.1093/infdis/jit004
10. Marzi A, Engelmann F, Feldmann F, Haberthur K, Shupert WL, Brining D, et al. Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates. Proc Natl Acad Sci U S A. 2013;110:1893–8. http://dx.doi.org/10.1073/pnas.1209591110
11. Garbutt M, Liebscher R, Wahl-Jensen V, Jones S, Möller P, Wagner R, et al. Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J Virol. 2004;78:5458–65. http://dx.doi.org/10.1128/JVI.78.10.5458-5465.2004
12. Rose NF, Roberts A, Buonocore L, Rose JK. Glycoprotein exchange vectors based on vesicular stomatitis virus allow effective boosting and generation of neutralizing antibodies to a primary isolate of human immunodeficiency virus type 1. J Virol. 2000;74:10903–10. http://dx.doi.org/10.1128/JVI.74.23.10903-10910.2000